Voltage-gated delayed rectifier potassium channel KCNH1

BE0005191ProteinHumansKCNH1

Pore-forming (alpha) subunit of a voltage-gated delayed rectifier potassium channel that mediates outward-rectifying potassium currents which, on depolarization, reaches a steady-state level and do not inactivate (PubMed:10880439, PubMed:11943152, PubMed:22732247, PubMed:25420144, PubMed:25556795, PubMed:25915598, PubMed:27005320, PubMed:27325704, PubMed:27618660,... It is acted on by 2 drugs in DrugBank.

Gene name
KCNH1
UniProtKB entry
O95259Swiss-Prot
Cellular location
Cell membrane
Residues / weight
989 residues · 111,422 Da
Also known as
EAG · EAG channel 1 · EAG1 · Ether-a-go-go potassium channel 1 · h-eag

Resolves to

Protein
UniProtO95259UniProt nameKCNH1_HUMAN
Gene
HGNCHGNC:6250NCBI Gene3756GeneCardsKCNH1
Pharmacology
IUPHAR/GtoPdb570KEGGhsa:3756
Structure
PDB5J7E
Drugs

What you can answer from here — as of October 08, 2024

2DrugsApproved to experimental, with action, bond type and pharmacological action
Sign in
12GO termsFunction, process and component, as structured annotations
Sign in
3Pfam domainsDomain architecture mapped to Pfam families and clans
Sign in
16+ReferencesStructured and connected to the statements they support
Sign in

Which approved drugs act on Voltage-gated delayed rectifier potassium channel KCNH1, how selective are they, and which programs against it are still in active trials?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In